Literature DB >> 8374844

Report of the Canadian Hypertension Society Consensus Conference: 4. Hypertension in the elderly.

R A Reeves1, J G Fodor, C I Gryfe, C Patterson, J D Spence.   

Abstract

Several knowledge gaps, which made evidence-based guidelines impossible in 1985, have since been filled. There is now unequivocal evidence that treatment of isolated systolic hypertension benefits elderly patients, as does treatment beyond the age of 75 years. Pseudohypertension, although occasionally problematic, is not common and is not a reason to neglect the treatment of elderly patients, including those with isolated systolic hypertension. In general, long-term antihypertensive treatment of the elderly is well tolerated and does not cause important decreases in mental function. Comparative drug studies continue to accumulate; most show no clinically significant general differences between drugs, aside from the somewhat decreased efficacy and tolerability of beta-blockade in elderly patients. As in the young, certain drugs may be preferred in the presence of other conditions--e.g., congestive heart failure or diabetes.

Entities:  

Mesh:

Year:  1993        PMID: 8374844      PMCID: PMC1485338     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  26 in total

1.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

2.  Pseudohypertension in the elderly.

Authors:  J D Spence; W J Sibbald; R D Cape
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

3.  Some lessons in cardiovascular epidemiology from Framingham.

Authors:  W B Kannel
Journal:  Am J Cardiol       Date:  1976-02       Impact factor: 2.778

4.  Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.

Authors:  A Amery; W Birkenhäger; P Brixko; C Bulpitt; D Clement; M Deruyttere; A De Schaepdryver; C Dollery; R Fagard; F Forette
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

5.  Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a Department of Veterans Affairs cooperative study. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  W C Cushman; I Khatri; B J Materson; D J Reda; E D Freis; G Goldstein; E A Ramirez; F N Talmers; T J White; S Nunn
Journal:  Arch Intern Med       Date:  1991-10

Review 6.  Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults.

Authors:  R B Haynes; Y Lacourcière; S W Rabkin; F H Leenen; A G Logan; N Wright; C E Evans
Journal:  CMAJ       Date:  1993-08-15       Impact factor: 8.262

Review 7.  Peptides as targets for antihypertensive drug development.

Authors:  T Hedner; X Sun; I L Junggren; A Pettersson; L Edvinsson
Journal:  J Hypertens Suppl       Date:  1992-12

8.  Hypertension treated by salt restriction.

Authors:  T Morgan; W Adam; A Gillies; M Wilson; G Morgan; S Carney
Journal:  Lancet       Date:  1978-02-04       Impact factor: 79.321

9.  Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.

Authors:  D G Wong; J D Spence; L Lamki; D Freeman; J W McDonald
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

10.  Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone.

Authors:  S B Hulley; C D Furberg; B Gurland; R McDonald; H M Perry; H W Schnaper; J A Schoenberger; W M Smith; T M Vogt
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

View more
  9 in total

1.  Beta-blockers as first-line therapy for hypertension.

Authors:  G A Heckman; A Papaioannou; W Parkinson; C A Patterson
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

2.  Contemporary practice patterns in the management of newly diagnosed hypertension.

Authors:  F A McAlister; K K Teo; R Z Lewanczuk; G Wells; T J Montague
Journal:  CMAJ       Date:  1997-07-01       Impact factor: 8.262

Review 3.  [Hypertension. A new way to approach an old problem].

Authors:  M Aubin
Journal:  Can Fam Physician       Date:  1996-04       Impact factor: 3.275

4.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

5.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

6.  Treating hypertension. Are the right drugs given to the right patients?

Authors:  M D Beaulieu; L Dufresne; D LeBlanc
Journal:  Can Fam Physician       Date:  1998-02       Impact factor: 3.275

Review 7.  Management of isolated systolic hypertension.

Authors:  A Tonkin; L Wing
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 8.  Canadian Hypertension Education Program: the evolution of hypertension management guidelines in Canada.

Authors:  Ross D Feldman; Norman R C Campbell; Katherine Wyard
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

9.  First-line first? Trends in thiazide prescribing for hypertensive seniors.

Authors:  Steve Morgan; Kenneth L Bassett; James M Wright; Lixiang Yan
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.